Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetologia (2018) Vol. 61, Iss. 12, pp. 2461-2498
Open Access | Times Cited: 1344

Showing 1-25 of 1344 citing articles:

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Frank L.J. Visseren, François Mach, Yvo M. Smulders, et al.
European Heart Journal (2021) Vol. 42, Iss. 34, pp. 3227-3337
Open Access | Times Cited: 4264
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, David A. D’Alessio, Judith Fradkin, et al.
Diabetes Care (2018) Vol. 41, Iss. 12, pp. 2669-2701
Open Access | Times Cited: 3144
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1145
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetes Care (2019) Vol. 43, Iss. 2, pp. 487-493
Open Access | Times Cited: 1050
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Molecular Metabolism (2020) Vol. 46, pp. 101102-101102
Open Access | Times Cited: 962
KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Ian H. de Boer, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2020) Vol. 98, Iss. 4, pp. S1-S115
Open Access | Times Cited: 955
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
Darren K. McGuire, Weichung Shih, Francesco Cosentino, et al.
JAMA Cardiology (2020) Vol. 6, Iss. 2, pp. 148-148
Open Access | Times Cited: 880
Chronic kidney disease
Kamyar Kalantar‐Zadeh, Tazeen H. Jafar, Dorothea Nitsch, et al.
The Lancet (2021) Vol. 398, Iss. 10302, pp. 786-802
Open Access | Times Cited: 874
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial
Michael E. J. Lean, W. S. Leslie, Alison C. Barnes, et al.
The Lancet Diabetes & Endocrinology (2019) Vol. 7, Iss. 5, pp. 344-355
Open Access | Times Cited: 756
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole K. Jeppesen, et al.
The Lancet (2021) Vol. 397, Iss. 10278, pp. 971-984
Closed Access | Times Cited: 751
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 670
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías, et al.
The Lancet (2021) Vol. 398, Iss. 10295, pp. 143-155
Closed Access | Times Cited: 655
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 572
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Marc Foretz, Bruno Guigas, Benoı̂t Viollet
Nature Reviews Endocrinology (2019) Vol. 15, Iss. 10, pp. 569-589
Closed Access | Times Cited: 523
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse, Deborah J. Wexler, Απόστολος Τσάπας, et al.
Diabetologia (2019) Vol. 63, Iss. 2, pp. 221-228
Open Access | Times Cited: 462
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
Richard E. Pratley, Aslam Amod, Søren T. Hoff, et al.
The Lancet (2019) Vol. 394, Iss. 10192, pp. 39-50
Closed Access | Times Cited: 445
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato, Steven E. Kahn, Imre Pávó, et al.
The Lancet (2021) Vol. 398, Iss. 10313, pp. 1811-1824
Closed Access | Times Cited: 434
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Hyo Shin Yoon, Chung Hwan Cho, Myeong Sik Yun, et al.
Nature Microbiology (2021) Vol. 6, Iss. 5, pp. 563-573
Closed Access | Times Cited: 388
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 383
Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis
Matti Uusitupa, Tauseef Khan, Effie Viguiliouk, et al.
Nutrients (2019) Vol. 11, Iss. 11, pp. 2611-2611
Open Access | Times Cited: 353
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Sandeep R. Das, Brendan M. Everett, Kim K. Birtcher, et al.
Journal of the American College of Cardiology (2020) Vol. 76, Iss. 9, pp. 1117-1145
Open Access | Times Cited: 347
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Carolyn F. Deacon
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 329
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 315
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
Matthew Capehorn, Andrei‐Mircea Catarig, Julie Kjærulff Furberg, et al.
Diabetes & Metabolism (2019) Vol. 46, Iss. 2, pp. 100-109
Closed Access | Times Cited: 304
Clinical Use of DPP-4 Inhibitors
Baptist Gallwitz
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 292
Page 1 - Next Page

Scroll to top